WELCOME TO SYNOSIA THERAPEUTICS


Synosia Therapeutics develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. We use cutting-edge technologies and creative clinical study designs to de-risk our compounds before moving into larger, more extensive Phase II and Phase III programmes. We currently have six clinical-stage compounds in our pipeline for neurological and psychiatric diseases with high unmet medical need, including Parkinson’s and Alzheimer’s disease. For doctors, this means potential new treatment options for debilitating neurological conditions. For patients, it could mean vast improvements in quality of life.
hands purple
BioBusiness 2010 – Roche and Synosia:
Establishing a Mutually Beneficial Partnership in CNS
Read highlights of the joint Roche and Synosia presentation given at BioBusiness (London) in Q1 2010, which summarises the Roche-Synosia partnership from its early beginnings to the first positive proof-of-concept data.

Learn More


 

Pipeline


Download Company Brochure PDF
Get the fast facts on Synosia

Learn More
BioBusiness Network 2007 Award Winner
EMAIL REGISTRATION
Sign up for regular updates
on Synosia.
Synosia Therapeutics adopts a privacy policy and will not disclose your email address or details to any third party.
Action you wish to take:
Your email address: